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Abstract
The Mediterranean region encompasses countries that surround Mediterranean 
Sea. Due to its position at the intersection of Eurasia and Africa it has often been a 
route of human migrations during history, which contributed to its high biodiver-
sity. People living in this area had been exposed to the episodes of natural selection 
that led to the establishment of specific genetic variations, for which is thought to 
carry a certain adaptation. Some recent studies have shown that genetic adaptations 
are probably related to the immune defense against infectious pathogens. One of 
the most recognizable disease of the region is familial Mediterranean fever (FMF), 
a prototype of a monogenic autoinflammatory disease. FMF is predisposed by the 
mutations in the Mediterranean fever (MEFV) gene that encodes inflammasome 
regulatory protein - pyrin. Specific variations of several other genes have been 
proposed to confer a protection against Plasmodium malariae parasite. Some of 
these are hemoglobin S (HbS), thalassemia, glucose-6-phosphate dehydrogenase 
deficiency, ovalocytosis, and mutation in the Duffy antigen (FY). In this chapter we 
will summarize important genetics and pathogenesis features of diseases com-
monly encountered in the Mediterranean region with a short discussion of potential 
adaptations that they may carry.
Keywords: familial Mediterranean fever, thalassemia, malaria, hemoglobin S, 
Duffy antigen, heterozygote advantage
1. Introduction
The Mediterranean region encompasses the lands surrounding the 
Mediterranean Sea; on the north there is Southern Europe and Anatolia, on the 
south North Africa, and on the east the countries of Levant. The Mediterranean 
region has a specific climate, with mild winters and hot, dry summers, which sup-
ports the characteristics of the Mediterranean flora and fauna. The region’s location 
at the intersection of Eurasia and Africa has contributed to the high biodiversity of 
its inhabitants, including people. Beside climate, this region has historically been 
the most frequent route of human migrations, as it is today.
Given the specific environment influences, several important genetic variations 
occurred and persist in people living in this area. Some of the genetic adaptations 
carry a certain degree of protection against infectious agents, but at the same time, 
when in an inadequate genotype, they can cause health disorders. This chapter 
will describe and discuss the most common types of genetic variations in the 
Mediterranean area related to adaptation and / or susceptibility to disease.
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2. Mediterranean fever (MEFV) gene mutations
2.1 Protein pyrin
One of the most recognizable diseases of the Mediterranean region is Familial 
Mediterranean Fever (FMF), a prototype of a monogenic autoinflammatory 
disease, associated with mutations in the MEFV gene that encodes for protein 
pyrin. Autoinflammatory disorders are characterized by dysregulation of innate 
immune response, unlike autoimmune diseases that are primarily mediated by 
adaptive immunity. However, approximately in a third of FMF patients pathogenic 
MEFV mutation is not identified, hence the diagnostic criteria for FMF still rely on 
clinical manifestations [1, 2]. The MEFV gene is composed out of 10 exons and 13 
introns, which make 781 amino acids (aa) long, multifunctional, protein pyrin. One 
of its first described functions is the assembly of an inflammasome. Pyrin acts as 
a pattern recognition receptor (PRR) that senses intracellular danger signals after 
which it binds to an adaptor protein and oligomerizes to form a pyrin inflamma-
some. Subsequently, inflammasome recruits and activates caspase-1, which further 
cleaves pro-inflammatory molecules, such as interleukin (IL)-1β and IL-18 [1, 3, 4].
As a PRR, pyrin seems to recognize downstream effects of a pathogen-driven 
modification and/or inactivation of RhoA GTPases - molecules that regulate actin 
dynamics [3]. By sensing a disturbance in actin signaling, pyrin recognizes common 
virulence mechanisms and starts an immune response. Several pathogen bacteria 
employ actin cytoskeleton for their invasion and survival, and by secretion of 
Rho-inactivating cytotoxins they were shown to activate pyrin inflammasome (e.g. 
Clostridium, Vibrio parahaemolyticus, Bordetella pertussis, Yersinia pestis) [5–7].
Besides, pyrin regulates process of autophagy a highly specific degradation of 
inflammasomes components. With this process pyrin suppresses IL-1β production, 
thereby preventing an excessive inflammation. Additionally, autophagy-based 
secretory pathway enables a group of proteins to exit cytoplasm without entering 
Golgi apparatus, among which is IL-1β [8, 9]. Hence, MEFV mutation-induced 
alterations affect this pathway and may facilitate interleukins secretion.
The pyrin activation requires at least two independent processes: dephosphory-
lation and pyrin inflammasome maturation involving microtubule dynamics [2, 7]. 
In FMF patients with pathogenic MEFV variants there is a hyperreactive state of 
the pyrin inflammasome. It seems that the second control mechanism of pyrin 
activation is lacking, and that pyrin is maintained inactive only by phosphorylation. 
Mutations in the exon 10 do not impact pyrin phosphorylation but may affect the 
control mechanism of microtubule dynamics [4, 7].
2.2 The MEFV mutations and their effect
According to the Infevers registry (the registry of hereditary autoinflammatory 
disorders mutations) there are 377 nucleotide variants identified in the MEFV gene 
so far. Most of them are benign and not involved in pathogenesis of FMF.
The FMF has long been considered an autosomal recessive disease, but with 
description of cases with heterozygote MEFV mutations this definition has changed. 
The mutations may express their effect in either a recessive or a dominant man-
ner, depending on their location in the gene. Generally, those in the exon 10 are 
considered recessive, while other manifest their effect in a heterozygous state and 
are considered dominant (gain-of-function). The most frequently identified FMF-
causing MEFV variants are in the exon 10 and encompass M694V (c.2080A > G), 
M680I (c.2040G > C), and V726A (c.2177 T > C) missense mutations, with the car-
rier frequency of ~10% in the populations of the Mediterranean region [2, 4, 8, 10].
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In order to achieve a better classification of pathogenic MEFV mutations, and to 
set a guidelines for genetic diagnostic testing of hereditary recurrent fevers, Shinar 
et al. [11], adopted the final consensus document that proposed a group of bialelic 
mutations to be used for definition of FMF. This group comprises 14 mutations, 
9 of which are clearly pathogenic (M694V, M694I, M680I, V726A, R761H, A744S, 
I692del, E167D, and T267I), while 5 mutations are designated as of unknown 
significance (E148Q , K695R, P369S, F479L, and I591T).
Depending on the type of mutations, permissive environmental factors and 
genetic background, clinical picture of FMF may vary from typical recurrent 
inflammatory attacks to mild symptoms or asymptomatic cases. The most frequent 
symptoms are recurrent episodes of fever with serosal inflammation, arthralgia 
or arthritis, abdominal pain, and localized erythematous skin rash. Episodes are 
self-limited and usually resolve within 48-72 h. Heterozygous patients usually 
have milder symptoms and shorter and less frequent attacks. Some asymptomatic 
carriers may have elevated inflammatory and oxidative stress biomarkers [4, 10, 
12, 13]. The most concerning long-term complication is renal amyloidosis, and 
renal transplantation is the choice in most end-stage renal disease [14, 15]. Standard 
treatment is a prolonged use of colchicine, although there are resistant cases. One 
potential cause of resistance is the vitamin D deficiency in these patients [16–18].
The M694V homozygote mutation is mostly associated with early onset of 
disease and severe course. It seems that environmental factors have stronger influ-
ence on this mutation [19, 20]. It is interesting to note the impact of environmental 
factors, since patients of the same ethnicity have different phenotype depending on 
the country they live in, i.e. the Eastern or Western Europe. Besides, a set of addi-
tional factors influence the phenotype, such as patient’s age and sex, micro-RNAs, 
immune factors (HLA I gene A), and microbiota [11, 20–22].
2.3 Potential heterozygote advantage of MEFV mutations
The higher frequency of MEFV mutations among multiple populations in the 
Mediterranean region suggests an existence of a heterozygote advantage. Mostly 
accepted theories explaining this assumption are those that recognize mutations 
as an adaptation to yet undetermined endemic infectious agent or, more probably, 
a group of agents. It seems that MEFV’s exon 10 had been exposed to the episodic 
positive selection in primates [2, 4, 23, 24].
Several bacteria secrete invasive factors (toxins) that covalently modify RhoA 
or its regulators. Other may inhibit pyrin inflammasome assembly by keeping it 
in the phosphorylated state, such as a protein YopM produced by bacteria Yersinia 
enterocolitica. Pyrin activation occurs when RhoA GTPases are disabled to promote 
their downstream signaling. In that sense, bacteria Yersinia pestis (bubonic plague- 
bacterium) is proposed as a possible agent that had led to the selection of gain-of-
function MEFV mutations [25]. Other hypotheses imply that mutated pyrin may 
confer a protection against tuberculosis or brucellosis, but without direct evidence 
[2]. Potential association between mutated pyrin and defense against tuberculosis 
is within the processes of autophagy and inflammasome activation. Mycobacterium 
tuberculosis is capable of arresting phagolysosome biogenesis in macrophages and 
prevents inflammasome activation by its Zn-metalloprotease, while mutated pyrin 
mediated stimulation of autophagic pathways may overcome this block [2, 26, 27].
2.4 Diversity of MEFV mutations
Higher frequency of pathogenic MEFV mutations in the Mediterranean basin 
is mainly explained by a founder effect and balancing selection. The M694V and 
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V726A mutations seem to emerge in human genome about 2000 years ago, accord-
ing to their association with specific microsatellite haplotypes in different popula-
tions [21, 28]. Presence of the E148Q (c.442G > C) mutation in different ethnic 
groups in the region supports the hypothesis of its recurrent nature or founder 
effect, probably stemming from the Asian countries, such as China and India, 
where E148Q is also frequent [20, 29]. The M694I (c.2082 G > A) mutation is merely 
present in North Africa and is estimated that occurred in an indigenous population 
of Berbers before colonizations in the 7th century BC [4, 20].
The M694V, M694I, M680I, and V726A mutations are most common in the 
Eastern Mediterranean countries, that is in Turkish, Armenian, Arab, and Jewish 
populations (Figure 1). The carrier rate of the mutations in these populations is 
estimated to be 1:5 to 1:7. Consequently, FMF mainly affects people of these ethnici-
ties [2, 5, 19, 30–32]. The prevalence of MEFV mutations and FMF is much lower 
in the Western Mediterranean countries (France and Spain). Actually, the ethnic 
origin of these patients is usually from populations with higher mutation frequen-
cies. Also, higher prevalence of homozygous mutations in the East might reflect the 
consequence of a local custom of consanguinity marriages [20, 33, 34].
Beside differences in MEFV mutations distribution between countries, there are 
variations within countries as well. For example, in Turkey, 94% of diagnosed FMF 
patients were from central-western parts of the country. However, more than a half 
of them had a family origin from the eastern provinces, pointing to the migration 
routes of mutations and disease [19, 35, 36]. The similarity between MEFV muta-
tions present in Turks and Jordanians can also be explained by the local migrations, 
during the Ottoman Empire [20, 37]. The M694V mutation is the most common 
in Arab FMF patients. Unlike others, Arabs in North Africa have higher rate of 
M694I mutation that is probably acquired through the intermarriages with the local 
autochthonous population [20, 31, 38–43].
There is a dissimilar pattern of MEFV mutations among Jewish population, 
as there is a number of distinct Jewish ethnic groups in Europe. Although the 
aforementioned mutations are mostly present in Jewish FMF patients, their 
exact frequencies differ depending on a country and ethnic group [16, 23]. For 
example, high carrier rate of M694V is identified in Jewish FMF patients living in 
North Africa (Morocco) (11.1%) and Iraq (2.9%), but is rarely observed among 
Ashkenazim [20], while the V726A is prevalent among Ashkenazi (7.4%) and Iraqi 
Jews (12.8%) [44]. In the study of MEFV mutation prevalence in the Israeli society, 
M694V was common mutation among non-Ashkenazi Jews, E148Q was observed in 
Figure 1. 
Allele frequencies of common MEFV mutations in FMF patients (%).
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patients of all ethnic groups, while K695R (c.2084A > G) seem to be characteristic 
mutation present in Jews [45]. In Sephardic Jews, the overall MEFV mutation carrier 
rate is between 1:8 and 1:16 [46], M694V is predominant, while other mutations, 
such as E148Q , P369S (c.459G > T), K695R and V726A, are rare [16].
The M680I mutation is common in Armenians and is associated with milder 
phenotype of the disease. Nevertheless, Armenian patients with FMF have common 
pathogenic mutations as the previous populations, such as M694V (~50%), fol-
lowed by V726A, M680I, and R761H (c.2282G > A) [10, 30, 32].
The E148Q mutation is the most frequent sequence alteration in the general 
population, but its clinical significance is still debatable. It is mostly encountered in 
a heterozygous state in asymptomatic individuals. When in homozygous state it is 
associated with FMF-like disease, with mild symptoms and later onset of disease. 
Thus, with regard to the SHARE recommendations heterozygous E148Q does not 
support the diagnosis of FMF [2, 5, 10, 11].
The P369S and K695R are rare mutations with reduced penetrance, often found 
in asymptomatic carriers or in complex alleles in FMF patients [23, 30, 47]. They 
were relatively common in general Ashkenazi Jewish sample in the USA, with the 
carrier frequency of ~1:5 in FMF patients [16]. The P369S was the most frequent 
mutation in healthy Armenians and it might ameliorate the phenotypic presentation 
of the co-existing exon 10 mutations in patients. P369S homozygotes were even 
observed among the asymptomatic Ashkenazi Jews [16, 30].
Unexpectedly high K695R mutation rate was determined in the countries of 
Central and South-Eastern Europe. This region is characterized with limited 
heterogeneity of MEFV mutations, with only eight different mutations determined 
in healthy subjects and FMF patients (K695R, E148Q , V726A, M694V, F756C, 
I591T, S730F and A744S). The K695R mutation was most common mutation, found 
in 40% of healthy and 32% of FMF patients, which supports the idea that this is a 
common mutation for this region [13, 48].
One another MEFV variation of unknown significance is the R202Q (c.605G>A), 
often considered a polymorphism due to its high heterozygous frequency, among 
healthy individuals. Due to its poor conservation during evolution it is assumed it 
appeared later compared to other common mutations [49]. The R202Q alteration in 
homozygous state was associated with FMF-like symptoms in some cases [47, 50]. In 
our study of MEFV distribution in Serbia, 45% of healthy individuals had heterozy-
gous R202Q , while 10% were homozygotes. Although considered healthy, the homo-
zygotes reported self-limited episodes of fever of unknown origin and unspecific 
abdominal pain [13]. The results indicate a pathogenic role of R202Q homozygosity, 
perhaps along with other permissive environmental and genetic factors of a patient.
In isolated populations there is a greater chance for arising of specific genotypes. 
One example of specific MEFV mutation distribution is an island of Cyprus, due to 
its distinct ancestry and relative isolation in the Mediterranean. The MEFV muta-
tions carrier rate in the Greek-Cypriot patients suspected for FMF is 1:25, with 
V726A, M694V, E167D (c.501G > C) and F479L (c.1437C > G) being the most com-
mon mutations. F479L is very rare elsewhere but in Greek-Cypriots its frequency is 
20.6%. Interestingly, F479L was always co-inherited in cis with E167D mutation. It 
is hypothesized that F479L originated in Cyprus as a founder mutation, from where 
it spread further [51].
It would be ideal when every population would perform a genetic testing for 
MEFV mutations and accordingly establish a set of the most frequent, which could 
be used in a screening for suspected FMF patients, as well as other inflammatory 
conditions, since MEFV mutations are found to be a modifying factor in a number 
of inflammatory and autoimmune diseases [52].
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3. Behcet’s disease
Behcet’s disease (BD) is an autoinflammatory and polygenic disease, more 
frequent in Mediterranean countries than in rest of Europe. Most cases are identi-
fied in countries of the Middle East and along the ancient Silk Route. The highest 
prevalence among Mediterranean countries is probably in Turkey, with estimated 
prevalence of 4.2/1000 in Istanbul [53]. This is a rare, sporadic, multi-systemic 
disease with undetermined cause. The main clinical features are constitutional 
symptoms and recurrent fever, oral aphthous, genital ulcers, with gastrointestinal, 
musculoskeletal, neurological, and vascular involvement [54].
Several host genetic factors are implicated in the pathogenesis of BD. The 
strongest is the association with the major histocompatibility complex HLA–B51 
allele, which increases the risk of disease for about 6-fold. Approximately 50% of 
BD patients possess this HLA variant. Besides, HLA-B51 contributes to the specific 
clinical features in BD such as less severe disease course, but a higher frequency of 
ocular manifestations [55, 56].
Behçet’s disease can be a comorbidity of FMF, and vice versa, MEFV mutations 
are common finding in BD patients. Some MEFV alterations are detected more 
often in BD patients than healthy subjects, such as P706 polymorphism. In a cohort 
of Turkish patients, clinical association was found between heterozygous MEFV 
mutation, principally M694V, and vascular involvement [51, 55, 57].
Interestingly, arthritis in BD is self-limiting and nondestructive in nature, 
pointing to the existence of an inherited protective factor/s. Such a role has been 
observed for plasminogen activator inhibitor 1 (PAI-1), which levels were higher in 
synovial fluid of BD patients than healthy. PAI-1 acted protective against destruc-
tive arthritis but had promoting effect towards hyperfibrinolysis in BD vascu-
lopathy. However, PAI-1 common polymorphism 4G/5G was not associated with 
pathogenesis nor development of thrombosis in these patients [58–60].
Besides, several other alterations are described to influence BD occurrence 
and course, including MHC class 1 polypeptide-related sequence, T cell mediated 
cytokine dysregulation (of IL-6, IL-8, IL-10), DNA methylation, etc. [55, 61].
4. Pathophysiology of β-thalassemia syndromes
4.1 Introduction
Genetic disorders referred as the ἀ- and β-thalassemias are caused by defective 
hemoglobin (Hgb) chains (ἀ or β) synthesis and are mostly inherited as a Mendelian 
recessive [62–64]. The name of the disease” thalassemia” is derived from the Greek 
words: thalassa (sea) and haima (blood), implicating the geographical region where 
the disease was initially described due to its high prevalence. Β-thalassemia occurs 
mostly in people with origins near the Mediterranean Sea, Greece, Italy (Sicily, 
Calabria and Sardinia), Turkey, Middle East, India, Southern China, Sub Saharan 
Africa, south America and in the populations of Sephardic Jews and Arabs, with 
Cyprus (14%) and Sardinia (10,3%) having the highest carrier frequency. However, 
the other form of the disease, ἀ-thalassemia, is the most common among the people 
form the Far East, China, Vietnam, Laos, and Cambodia [63, 64].
Although considered as the rare form of the disease, it is confirmed that around 
68,000 children annually are born with the various forms of thalassemia syn-
dromes, whereas 1.5-5% of the worldwide population are considered as the carriers 
of these genetic abnormalities [65–68]. The high frequency of these mutations is 
considered as an evolutional answer to the malaria infections, providing protection 
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against Plasmodium falciparum for the genetic mutation carriers. The aberrant Hgb 
synthesis reduces the half-life of erythrocytes which disables completion of parasite 
maturation cycle [63]. Moreover, the same type of genetic aberrance has been con-
firmed in consanguineous marriages in some countries [64]. However, high rate of 
the migrations of populations caused that individuals with thalassemia-syndromes 
may be found in the US, Australia, Canada, South America and North Europe, 
making it a global health care burden [65–68]. Moreover, the general epidemiologi-
cal estimation is that the prevalence of thalassemia-syndromes is about to increase, 
taking into the consideration the fact that infant mortality declines in low-income 
and middle-income countries [68].
Thalassemias are heterogeneous, inherited, monogenic, Hgb disorders and are 
initially classified as ἀ or β, depending whether genes that control ἀ- or β-globin 
chains synthesis are defective. This knowledge implicates that β-thalassemias 
occur when synthesis of the β-globin chains is reduced (β+) or absent (β-) [62–64]. 
Moreover, clinical, and hematological manifestations depend on how many of 
the genes that code β-globin synthesis are defective and whether those defects are 
homozygous or heterozygous. The phenotype diversity and wide range of disease 
severity lead to introduction of the concept of β-thalassemia-syndromes.
According, three culprit forms that comprise the β-thalassemia-syndromes are 
defined and classified by increasing severity of the symptoms: 1) β-thalassemia 
carrier state, also known as β-thalassemia minor, “heterozygous thalassemia” or 
“thalassemia trait”, 2) β-thalassemia intermedia and 3) β-thalassemia mayor, also 
referred as “Cooley’s anemia” and “Mediterranean anemia”, very severe phenotype, 
that requires blood transfusion for survival (transfusion-dependent anemia) and 
has a questionable outcome. Besides these forms, there are other identified types of 
β-thalassemias, that are associated with various Hgb and/or clinical abnormalities 
or may be autosomal dominant [63, 64]. Persons with most severe forms (major) 
are homozygotes or compound heterozygotes for β0 or β + genes, intermedia type 
may be homozygotes or compound heterozygotes, while the mildest form is pre-
dominantly heterozygotes [62–64].
In the past two decades, individuals affected with β-thalassemia-syndromes are 
experiencing tremendous improvement in the quality of life and overall survival, 
due to the timely diagnosis, adequate therapy, and monitoring of the disease. 
However, up to date, the only cure for the disease represents allogeneic hemopoietic 
stem-cell transplantation.
4.2 Molecular basis
The synthesis of β-globin chains in Hgb molecule physiologically is under 
control of two genes. Any genetic abnormality of the controlling genes, therefore, 
results in the absence or the reduction of the β-chain. The gene for β-chain is 
located in the short arm of chromosome 11, sharing the region and being arranged 
in the order of the development expression, with the functional genes for δ-globin, 
embryonic ε-globin, the fetal A-γ-globin and G-γ-globin, as well as a pseudogene 
(ψβ1) [63]. The molecular and clinical diversity of the β-thalassemias emerges 
from the data that more than 200 genetic mutations have been described up to 
date [63, 64, 68–70]. Accordingly, clinical, and hematological manifestation and 
patients’ prognosis depend on the basis of imbalance of the ἀ- and β-chains synthe-
sis, therefore from the type and the extent of the genetic disturbance.
The identified and defined genetic aberrations are silent mutations (silent 
β-globin), mild mutations (relative reduction of β-globin) and severe mutations 
(complete absence of β-globin, β0) [68]. Nevertheless, these mutations are identi-
fied mostly as single-nucleotide substitutions and insertions of single nucleotides 
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or small oligonucleotides causing the frameshifts in genes that code β-chains. The 
typical genetic abnormalities that were described are promoter mutations, being 
responsible for the milder phenotypes, whereas nonsense, initiation codon, splicing 
and frameshift mutations have been documented in more severe forms of thalas-
semia-syndromes, characterized with the complete absence of β-chains [62, 63]. 
Deletions of the gene are randomly identified aberrations, where the deletional 
removal of one or several genes from the chromosome 11 causes very rare forms of 
thalassemias, designated as δβ-, γδβ- and εγδβ-thalassemia [62].
An autosomal recessive pattern of thalassemia inheritance implicates that both 
parents have to be heterozygotes, owing a copy of a β-globin gene mutation. Possible 
outcomes in the affected family may be that every child has: 1) 25% chance of being 
affected, 2) 50% of being an symptom free and carrier, and 3) 25% of not being 
affected nor a carrier [63, 64].
4.3 Genetic modifiers
Pathophysiological perception why individuals with beta-thalassemia syn-
dromes may clinically appear very heterogeneous, is based on the perseverance of 
three group of factors that may modify the disease. These factors are designated 
as genetic modifiers and are explained as genetic variants that induce differences 
in disease phenotype [64]. Genetic variants that may impact the imbalance of 
globin chains are categorized as primary modifiers. The other pathogenetic fac-
tors that may alleviate the severity of β-thalassemia major are: coinheritance of an 
ἀ-thalassemia gene and fetal Hgb production, within the β-globin cluster and are 
classified as secondary modifiers [62, 68].
Coexistence of ἀ-thalassemia enables decreased ἀ-globin chain synthesis, there-
fore significantly reduces imbalance between the ἀ/non-ἀ-chain in erythrocytes 
[63]. Increased γ-chain synthesis, in adult life, encounters the excess of ἀ-chains, 
therefore enables the survival of the erythrocytes that contain fetal hemoglobin, 
marked as HbF cells. It may be that deletion mutation or point mutation within 
the β-globin gene cluster simultaneously trigger a rise in fetal Hgb production 
[62]. According to some research, the increase of HbF synthesis indicates a single 
nucleotide polymorphism in one of the γ-globin gene promoters or somewhere in 
the globin locus, resulting in the overexpression of the related gene [62]. It was 
reported that HbF, that is highly predominant in individuals with severe forms of 
thalassemia, may account for their improved survival [71]. Moreover, the inverse 
correlation of HbF levels and factors that reflect disease morbidity was observed, so 
as the finding that milder phenotypes present with the increased numbers of HbF 
cells [62, 72]. In addition to this knowledge, it was suggested that certain therapeu-
tic treatments (hydroxyurea) may induce the production of HbF, hence produce less 
of a need for blood transfusion [73].
Tertiary modifiers are recognized to be genetic and environmental factors that 
modulate disease complication rates. The results of the molecular studies revealed 
genetic polymorphisms as possible pathogenetic factors involved in cardiac iron 
overload, hyperbilirubinemia, and Gilbert disease, osteoporosis, and infections 
susceptibility, that occur in patients with β-thalassemia syndromes [63, 68, 74–76].
4.4 Pathophysiology
Essential pathophysiological determinant in β-thalassemia syndromes is the 
uncoupling of the synthesis of the ἀ- and the β-chain, where β-chain synthesis 
is reduced or absent, resulting in the accumulation of ἀ-globin tetramers in the 
erythroid precursors [62–64]. This phenomenon eventually leads to an ineffective 
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erythropoiesis, that is a key feature responsible for various pathophysiological 
consequences during the course of the disease. Erythrocytes and its precursors 
(mostly polychromatophilic erythroblasts) are filled with precipitated ἀ-globin 
tetramers, forming inclusive bodies, causing oxidative membrane damage and sub-
sequent apoptosis [62–64, 77]. Physiologically, biochemical detoxification would be 
efficient to eliminate harmful proteins from the affected cells. Nevertheless, in the 
severe forms of β-thalassemias these pathways are inefficient [62].
Premature erythroid cell death in the bone marrow (ineffective erythropoiesis) 
and in the peripheral blood (hemolysis) cause chronic microcytic-hypochromic 
hemolytic anemia, that is a persistent finding in persons with thalassemia. 
Interestingly, hemolysis is less notable in individuals with severe phenotypes of 
the disease [64]. Chronic hypoxia induces intensive and continuous erythro-
poietin production, resulting in the great expansion of the bone marrow (25–30 
times), subsequent skeletal deformities and the loss of the bone mass [63, 64, 68]. 
Simultaneously, a compensatory extramedullary hematopoiesis occurs, creating 
organomegaly, predominantly of spleen and liver [68]. Nevertheless, if the stimulus 
is extremely potent, all the cell in the body that express hematopoietic potential 
will be affected, resulting in the formation of the pseudotumors [78]. Hemolysis 
will trigger the formation of the gall stones and cholelithiasis and also contributes 
to splenomegaly development. Besides, the thalassemia-syndrome is recognized as 
a hypercoagulable state, since erythroid precursors, during the ineffective eryth-
ropoiesis, may become prothrombotic. Moreover, in association with platelets and 
coagulation disruption, the condition may result in serious vascular manifestations 
such as venous thrombosis [63, 64, 68, 79].
Besides ineffective erythropoiesis and anemia, iron overload also represents 
very important mechanism in the pathogenesis of the thalassemia, contributing 
to development of complications. Iron deposition within the reticuloendothelial 
system in the transfusion- dependent forms of β-thalassemia (major and interme-
dia) represents associated and secondary mechanism in the pathogenesis of iron 
overload. However, it is well defined that the most important pathogenetic factor in 
the hemochromatosis development represents increased iron absorption [80], due 
to the hepcidin downregulation and its deficiency [62, 63].
The apoptosis of the erythroid precursors causes subsequent synthesis and 
secretion of many factors that most likely inhibit hepcidin synthesis in the liver 
[62]. Coupled with this, it should be underlined that hepcidin functions as a 
negative iron regulator, delivering the information between the liver and the red 
blood cells. Its decreased concentrations result in the increased dietary iron absorp-
tion and in release of the iron from its storage (macrophages and hepatocytes). 
The final result is paradoxically and significant dietary iron absorption, regard-
less of the iron tissue deposition due to the blood transfusions and eventually 
 hemochromatosis [62].
The identified molecules that are released from the apoptotic erythroid precur-
sors are growth differentiation factor 15, twisted gastrulation 1, and erythroferrone, 
and all function as hepcidin expression inhibitors [68, 80–83]. The results have been 
conflicting so far, since some research demonstrated their significant increase in 
individuals with β-thalassemia [81, 82], while the others confirmed only increase 
of erythroferrone in animal models [84]. However, their exact function in the 
pathogenesis is yet to be elucidated. Nevertheless, the substitution of the synthetic 
hepcidins represents justified therapy option in patients with the severe forms, as 
already proven experimentally. However, this extensive and progressive iron over-
load in synergy with anemia may deteriorate already insufficient hematopoiesis. 
Iron overload, regardless of its pathogenesis, leads to hemochromatosis and organ 
damage [83, 85].
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4.5 Clinical findings
The main clinical features of β-thalassemia syndromes are anemia and iron 
overload, leading to severe and life threating consequences. The onset and the 
degree of the symptoms severity depend whether the affected individuals present 
as a homozygous phenotype (thalassemia major) or as a homozygotes or com-
pound heterozygotes (thalassemia intermedia). Correspondingly, individuals with 
β-thalassemia minor are usually asymptomatic and may be discovered incidentally, 
having only the discrete changes in the hematological findings.
The onset of symptoms will appear 12 months after the birth, [67–85], at the 
moment when HbF production switches to adult and physiological synthesis of 
HbA is yet to be established [86]. The infants will experience feeding problems, 
recurrent fevers, diarrhea, enlargement of the abdomen and the growth retarda-
tion. If the child has not been diagnosed prenatally, this is the point when the 
diagnosis of thalassemia is determined, and transfusion indicated [63, 64].
Microcytic-hypochromic hemolytic anemia is an obligatory finding in the 
affected individuals, predisposing them to progressive paleness and jaundice. 
Bone marrow expansion secondary to erythroid hyperplasia, lead to significant 
skeletal changes, creating abnormalities of the face and body. People with severe 
phenotypes most often experience frontal bossing, depression of the bridge of the 
nose, mandible and maxilla enlargement with the upper teeth exposure, bone pain, 
osteopenia and osteochondrosis. If spinal impairment occurs during the childhood, 
linear growth is delayed, resulting in the discordance in the length of upper and 
lower limbs [63, 64, 87]. The progressive enlargement of the abdomen is due to the 
hepatosplenomegaly, whereas the masses of extramedullar hematopoietic tissue 
may also be found in the chest or spinal column [63, 64].
Iron overload predominates in the most severe clinical phenotypes. Brown 
pigmentation of the skin, particularly in the areas exposed to the sun, reflects 
systemic hemochromatosis. Predominant sites for iron deposition tend to be spleen, 
liver, myocardium, pancreas, and endocrine glands. Although significant liver 
deposition of iron could be found, its function may be preserved for a long time 
[62]. Ultimately, liver cirrhosis may develop. Cardiac manifestations stand for the 
most adverse outcome of iron overload, whereas arrhythmias, dilated cardiomy-
opathy, and atrial or/and ventricular failure during the course of the disease lead 
to congestive cardiac failure. Endocrine complications primarily develop due to 
the insufficiency of the growth hormone (growth retardation) and sex hormones 
(hypogonadism). Additionally, hormone substitution therapy is commonly 
required for maintaining normal fertility. Other endocrine disturbances may be 
very diverse, including diabetes mellitus, hypothyroidism, hypoparathyroidism, 
hypocorticism, and panhypopituitarism. Pulmonary hypertension may contribute 
to the complexity of the cardiovascular manifestations by deteriorating left heart 
function [79, 88].
Other clinical features in β-thalassemia syndromes are osteoporosis, subclinical 
fractures, nutritional deficiencies, venous thrombosis, chronic B and/or C hepatitis, 
and infections. The risk of hepatocellular carcinoma in patients who develop liver 
cirrhosis remains unchanged even if the proper therapy is performed, due to the 
oxidative DNA damage triggered by chronic iron accumulation [79, 88].
4.6 Laboratory findings and Hgb analysis
Laboratory diagnosis of thalassemia is confirmed based on established red blood 
cells parameters, qualitative and quantitative Hgb analysis and, when necessary, 
molecular assessment. Erythrocyte count may be relatively high, whereas Hgb is 
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reduced <7 mg/dL, mean corpuscular volume (MCV) is between 50 and 70 fL and 
mean corpuscular Hgb (MCH) 12-20 pg. Peripheral blood smear demonstrates 
microcytosis, hypochromia, anisocytosis, poikilocytosis (dacrocytes and ellipto-
cytes), along with the erythroblasts. The number of reticulocytes may remain nor-
mal, without any diagnostic accuracy. In order to differentiate iron deficiency anemia 
form the thalassemia-syndromes, few formulas are available to calculate a thalassemic 
index, but should be performed with caution [63, 64, 89]. In biochemical terms, 
typical β-thalassemia presents with elevated ferritin levels >12 ng/mL, transferrin 
saturation increased to 75-100% and unconjugated hyperbilirubinemia [62, 88].
The most accurate method for β-thalassemia differentiation is quantitative HbA2 
determination. Considering that physiological HbF in adult population is commonly 
less than 1.5%, the results for HbA2 ranging between 3.6 and 7% are considered as 
definite thalassemia values. Nonconclusive or borderline cases, with HbA2 ranging 
between 3.2 and 3.6%, respectively, require further analysis [86, 89]. Additionally, 
PCR-based procedures or β-globin gene sequence analysis are necessary for diag-
nosis confirmation. Besides, in couples with increased risk, a prenatal diagnosis of 
thalassemia may be achieved by chorionic villi sampling (11th gestational week) or 
DNA analysis from harvested fetal cells (15-18th gestational week) [63, 64, 89].
4.7 Therapy approach
Conventional management of β-thalassemia syndromes includes blood trans-
fusion, iron chelation, splenectomy and hemopoietic stem-cell transplantation. 
The introduction of blood transfusion in regular management of β-thalassemia 
has enormously improved quality of life and survival of the affected individuals 
[62–68]. The mayor indication for its initiation, in previously diagnosed patients, 
should be low Hgb level (<7 g/dL), that lasts at least two weeks [64], concerning 
other clinical signs such as growth retardation, skeletal changes and splenomegaly. 
The therapeutic aim of transfusion is to maintain Hgb level at 9-10 g/dL or 11-12 g/
dL in cases of confirmed cardiovascular disease [63, 64, 68, 86]. Although life-
saving approach, blood transfusion has several adverse effects, with iron overload 
and viral infections (hepatitis B, C) being the most common [62–68].
The knowledge that iron cannot be excreted form the human body and that 
patients requiring constant blood transfusions tend to develop iron overload, lead to 
the regular assessment of iron body status. Most conventional method is determina-
tion of serum ferritin levels, that may be monitored in order to initiate chelation 
therapy or may be used as a biomarker of iron chelators efficiency. However, more 
reliable, yet non-invasive method of tissue iron accumulation has been developed. 
Magnetic resonance imaging has been successfully used for liver and cardiac iron 
overload, measuring a tissue iron concentration in mg of iron per gr of dry liver/
heart weight [63, 90, 91]. Also, iron binders (chelators) enable its elimination 
through feces and/or urine and should be initiated after approximately 10-20 
performed transfusions or with ferritin levels above 1000 mg/gL [64, 68].
Splenectomy is indicated in the following cases: enlarged spleen with the risk of 
rupture, severe cytopenia and in patients with the significant blood requirements. 
In patients with splenectomy, infections and subsequent sepsis remain the leading 
cause of mortality [63].
However, the only curable therapy for the thalassemia represents hematopoietic 
stem-cell transplantation [63, 64, 68]. Nevertheless, it was documented that a 
disease-free survival may be achieved in 80% in matched donors and even 65% in 
unrelated donors and umbilical blood cord stem-cells transplantation. Nevertheless, 
this therapy option is still associated with risk and complications, even in the high-
income countries [92].
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Considering the monogenic nature of the disease, the most challenging, yet 
possible therapy approach, may be an interference in the globin chains imbalance, 
achieved by gene therapy and genome editing [68]. Alternative pharmaceuti-
cal approaches would be use of agents acting as potent stimulators of late stage 
erythropoiesis and increased hepcidin expression, throughout its substitution or 
stimulation of its endogenous production. Even though there has been a substan-
tial progress in the development of therapy options for individuals affected with 
thalassemia, the best approach to the disease management remains prevention of 
thalassemia births throughout national screening programs [68].
5. Association of HbS, G6PD and FY gene polymorphisms and malaria
5.1 Introduction
Understanding the molecular mechanisms that underlies the adaptation is of 
crucial importance in evolutionary biology. Among the plethora of genes that 
causes adaptive variation in fitness-related features in natural populations, very few 
are identified [93, 94]. The hemoglobins, oxygen-carrying proteins, tightly connect 
cell metabolic activities with environmental conditions and thus represent conve-
nient system for analyzing adaptive changes [93, 94]. Also, inherited disorders of 
hemoglobin are the most common human monogenic diseases [95]. Each year, there 
are between 300,000 and 400,000 newborns with some of the serious hemoglobin 
disorders and up to 90% of them are born in low- or middle-income countries [96].
Hemoglobin is the oxygen-carrying protein of red blood cells (RBCs), normally 
formed of two α-globins and two β-globins that constitute adult hemoglobin A 
(HbA). Without specific medical treatment, the most severe hemoglobinopathies 
— HbSS homozygosity (sickle-cell disease) and the thalassemias major are not 
compatible with life after early childhood. People with HbAS, HbAC, HbCC, HbAE, 
HbEE, and the thalassemias minor have usually normal life expectancy and are 
rarely directly associated with morbidity [97].
Plasmodium spp. parasites represent vector-borne pathogens which attack the 
red cells of reptiles, birds, and primates [98]. Out of five Plasmodium species that 
parasitize and cause malaria in humans, P. falciparum and P. vivax are the most 
common in human populations. P. falciparum is endemic in tropical areas world-
wide, including Mediterranean [99]. Like the other four Plasmodium species, P. 
falciparum is injected into a human skin via female Anopheles spp. mosquitoes as 
a vector. Then, the sporozoites migrate to the liver where they attack hepatocytes 
and develop within them for 7–10 days. As a consequence, numerous merozoites 
are formed which, subsequently, enters erythrocytic stage of RBSs life cycle. In that 
time, typical features of malaria clinical picture develop [97, 98].
As a disease which is a main cause of morbidity and mortality, malaria caused 
by P. falciparum imposed remarkable evolutionary pressure on the human genome.. 
Also, malaria caused by P. falciparum is in relation with numerous genetic poly-
morphisms that are responsible for protection against this disease [97, 100]. 
Hemoglobin mutants S, glucose-6-phosphate dehydrogenase (G6PD) deficiency, 
and Dufy Antigen/Receptor for Chemokines (DARC) gene mutation are mostly dis-
tributed in the areas where P. falciparum malaria is endemic. These genes expression 
have high levels of prevalence in malaria endemic areas which is considered to be 
the consequence of their protective role against P. falciparum [101]. In this context, 
malaria can be defined as an infectious disease that has pronouncedely higher 
selective pressure on the human genome in comparison with all other infectious 
diseases [101]. Polymorphysms of the above-mentioned genes are typical examples 
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of Haldane’s idea of balanced polymorphism. According to this author, balanced 
polymorphism exists when certain genes have fixed high frequency in susceptible 
populations since enhanced fitness encompanied with heterozygotes multiple times 
overweights morbidity and mortality associated with homozygotes and compound 
heterozygotes [102].
5.2 HbS gene polymorphisms and malaria
Sickle hemoglobin (HbS) is best characterized genetic polymorphism tightly 
interconnected with malaria. HbS represents a structural variant of normal adult 
hemoglobin (HbAA) and results from a single point mutation (Glu → Val) on the 
sixth codon of the beta globin gene [103]. Homozygotes for hemoglobin S (HbSS) 
have sickle cell disease that further causes high morbidity and mortality. Also, 
heterozygous for HbS have 10-fold lower risk of dying from malaria compared to 
homozygous [97, 104, 105]. Heterozygotes (HbAS) have generally asymptomatic 
sickle cell disease which does not endanger their lives [106].
It has been found that, in the conditions of selection for fitness against malaria, 
nearly 45 generations (or 1000 years) were necessary to pass until sickle gene 
frequency reached a stable equilibrium [107]. People with HbAS have 50–90% 
lower parasite density [105] in comparison with individuals with normal hemoglo-
bin (HbAA). Sub-Saharan Africa is an area with closely 80% of people born with 
sickle cell anemia and where most P. falciparum malaria cases and deaths occur 
[108]. Besides sub-Saharan Africa, sickle cell anemia is present, although rarely 
with frequency higher than 20–25%, in the Mediterranean region, the Middle East, 
and the Indian subcontinent [95]. There is a strong connection between high HbS 
allele frequency and high malarial endemicity in the world although this finding is 
based on the observations made in Africa: HbS allele frequency gradually increases 
from epidemic areas to endemic areas in Africa which is in accordance with the 
hypothesis that malaria protection by HbS includes the enhancement of innate and 
acquired immunity to P. falciparum [109].
Knowledge of the existing relationship between malaria infection and  extension 
and prevalence of hemoglobinopathies in Mediterranean region are not new 
[102, 110]. Sickle-cell homozygous persons have short life expectancy and com-
monly die before adulthood. However, the gene responsible for sickle cell disease 
“hidden” within the genotype of heterozygous carrier can achieve high frequency 
due to resistance to P. falciparum [111].
There are lots of described biological mechanisms that are considered to be 
responsible for protection against malaria. First, there were only two mechanisms 
described regarding a manner in which the presence of HbS in heterozygotes 
protects against malaria: sickling of circulating infected RBCs and impaired parasite 
growth and oxidant damage [101]. It has been found that formation of sickle RBSc 
shapes under low oxygen presure occured more frequently in RBCs infected with 
P. falciparum compared to uninfected RBCs [112]. When parasite triggers sickling 
of erythrocytes once, sickled cells are removed by macrophages [113]. This action 
of may macrophages’possibly occurs due to their ability to produce and release 
numerous cytokines that further recruit more phagocytic cells [114]. In addition, 
it has been discovered that enchanced sickling was limited to RBCs infected with 
small Plasmodium forms [115]. On the other hand, impaired parasyte growth and 
oxygen damage was discovered thanks to in vitro studies [112]. In the conditions 
of normal oxygen pressure, there were no differences in the invasion, growth, 
and multiplication of P. falciparum in HbAS cells compared to HbAA RBCs. In the 
opposite, hypoxic consitions caused reduced fraction of P. falciparum in HbAS 
cells and a block in the maturation of ring forms to trophozoites and schizonts. 
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In addition, sickling and destruction of parasites in HbAS and HbSS RBCs at lower 
oxygen tensions (1–5%) more closely mimiced the micro-aerophilic environment of 
post-capillary venules in vivo [112].
The guiding hypothesis regarding the protective effect against malaria in people 
with HbAS suggests that decreased P. falciparum Erythrocyte Membrane Protein 
1 (PfEMP1) [116] expression on infected HbAS RBCs results in lower binding of 
infected cells to the endothelium [117]. As a consequence, only approximately 
one-half the cytoadherence was seen in infected HbAS RBCs. Archer and associates 
have proposed that oxygen-dependent HbS polymerization is a key factor for HbAS 
malaria resistance [118]. They found that intraerythrocytic P. falciparum parasites in 
HbAS RBCs at low oxygen concentrations arrest in cell cycle before DNA replication 
and that HbS polymerization is responsible for this growth arrest.
Among the genetic factors responsible for the protection from malaria is one of 
the complement regulatory proteins − complement receptor 1(CR1). The frequency 
of CR1 polymorphisms is high in a numerous of malaria endemic areas [100]. A 
major receptor for RBCs infected with P. falciparum is human protein CD36 [119]. 
CD36 can be involved in malaria by sequestering infected RBCs thus disabling the 
immune response to this parasite [120]. Some African populations have extremely 
high frequency of CD36 mutation and this CD36 deficiency causes susceptibility 
to severe form of malaria [121]. Important genetic factors involved in resistance to 
malaria are erythrocyte-binding antigens. Special attention was given to erythro-
cyte binding antigen-175 (EBA-175), a protein that binds to glycophorin A, thus 
enabling merozoite entry into erythrocytes [122].
An interesting study regarding host genetic factors responsible for malaria resis-
tance was conducted in Senegal, in the population of children and young adults that 
were 2 to 18 years old. Thanks to the results of this study, three candidate regions in 
the genome of these children were detected and one of them contains a gene related 
with the malaria infection in the 5q31q33 region [123].
One of the newest studies revealed that unfavorable microRNA (miRNA) com-
position in heterozygous HbAS or homozygous HbSS erythrocytes, leads to resis-
tance versus P. falciparum. When erythrocytes are infected with P. falciparum, a part 
of erythrocyte miRNAs can translocate into the parasite. LaMonte et al. found that 
HbAS and HbSS erythrocytes had high number of miR-451 and let-7i integrated 
into essential parasite messenger RNAs, as well as that these miRNAs, together 
with miR-223 are negative regulators of parasite growth [124]. miR-451 fuse with 
transcripts of the regulatory subunit of the parasite’s cAMP-dependent protein 
kinase (PKA-R) and reduce its translation. Therefore, it up-regulates the activity of 
its substrate PKA and disrupts multiple parasite developmental pathways [124].
Piel and associates created extensive geodatabase of HbS allele frequency 
and investigated geographical distribution of malaria [125]. Their HbS allele 
frequency map has shown that throughout majority of the African continent and 
in localized areas in Mediterranean, this allele is present with the frequency of 
>0.5%. According to this geodatabase research, in the Chalkidiki region of Greece, 
southeastern Turkey and in Central Sudan, frequency of this allele was even 
above 6% [125].
One of the models of how hemoglobiopathies protect from malaria is proposed 
by Killian associates [126] and reveals association between reduced cytoadher-
ence phenotype and parasitized hemoglobinopathic erythrocytes. This team used 
conditional protein export system and tightly synchronized cultures of P. falci-
parum. They have showed that exportation of proteins encoded by parasites across 
the parasitophorous vacuolar membrane is more advanced, faster and increased in 
amount in parasitized wild type erythrocytes in comparison with hemoglobino-
pathic erythrocytes.
15
Adaptation to Mediterranea
DOI: http://dx.doi.org/10.5772/intechopen.94081
Severe malaria is in relation with intraerythrocytic life cycle of P. falciparum and 
the pathological cytoadhesive behavior of parasitized erythrocytes [127, 128]. When 
parasite adheres to the endothelial cells of venular capillaries, it avoids clearance 
mechanisms of spleen. As a consequence, pathological sequelae form within the 
affected blood vessel [127, 128].
Pathological consequences of P. falciparum malaria can possibly be mediated by 
adhesion of infected cells to vascular endothelium either to other uninfected red 
cells (rosetting) or to platelets (clumping). It has also been found that variant of 
erythrocytes infected with P. falciparum do not have noticeable differences regard-
ing their adhesive phenotypes in comparison with erythrocytes of normal individu-
als infected with this parasite [129].
There are two main phenotypes of parasite-infected RBCs (iRBCs) and both 
express PfEMP1 [130, 131]. First type of iRBCs mediate iRBCs binding to the endo-
thelial receptors (“cytoadherence”) [132] and the second mediate iRBCs binding 
to uninfected RBCs (“rosetting”) [133, 134]. Different iRBCs phenotypes differ in 
various PfEMP1 that are responsible for binding of iRBCs to microvascular endo-
thelial cells, placental syncytiotrophoblasts or uninfected RBCs [135–137].
Usually, hemoglobin S does not increase IgG responses to various P. falciparum 
proteins [138], but it can potentially enhance IgG responses to PfEMP1, which 
is the main cytoadherence ligand and virulence factor [139]. In an in vitro study, 
HbAS affected the trafficking system that directs PfEMP1 to the surface of infected 
erythrocytes. Using cryo-electron tomography, it has been shown that within the 
cytoplasm of normal RBCs, the parasite proteins are transported to the surface via a 
parasite-generated host-derived actin cytoskeleton. In addition, hemoglobin oxida-
tion products disrupted this process in HbAS red cells [140].
Exact pathogenic mechanisms of malaria caused by P. falciparum are still 
unknown due to numerous parasite virulence factors, host susceptibility traits, 
and innate and adaptive immune responses that modify the occurrence of various 
malaria syndromes [141, 142].
The most important reason for the high frequency of hemoglobin disorders in 
tropical countries is natural selection through protection of heterozygotes against 
severe malaria. Protection observe in HbAS is reflected in protection against severe 
form of malaria and probably, to some extent, against mild malaria [129]. Natural 
selection is not the only mechanism responsible for high HbS gene frequency 
[102, 106, 107]. The others are high frequency of consanguineous marriages and 
epidemiological transition [98]. In addition, different distribution of some hemo-
globin disorders in different populations is an example of founder effects by their 
original inhabitants [143].
Thanks to the studies conducted in vitro, various researches united on general 
hypothesis that protection from malaria is the result of impairment in the inva-
sion and growth of P. falciparum parasites into HbAS red cells under conditions of 
low oxygen tension that were physiologically representative of in vivo conditions 
[112, 144]. Afterwards, a lot of alternative hypothesis have been developed includ-
ing the one that refers to the enhanced removal of parasite infected HbAS RBCs. 
This mechanism could be related with sickling of these cells under low oxygen 
tension [112, 115, 145] causes their premature destruction in the spleen [112]. 
Specifically, Shear and associates have observed that protective effect of HbS can be 
lost on the model of transgenic mice that were subjected to splenectomy [146].
There are few researches that suggest that protection against malaria can be 
achieved not only through innate immunity, but also via acquired immunity. For 
example, in populations naturally exposed to P. falciparum, protective effect of 
HbAS increases with age [147, 148]. This is in accordance with recent studies on 
a mouse model which proposes an immuno-modulatory mechanism mediated 
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throughout hemoxygenase-1 [149]. The problem with these findings when translat-
ing into human populations is metabolic difference between sickling disorders of 
mice and human sickle-cell traits [95].
5.3  Glucose-6-phosphate dehydrogenase (G6PD) gene polymorphisms and 
malaria
The Glucose-6-phosphate dehydrogenase (G6PD) is a “housekeeping” gene 
located on long (q) arm of the X chromosome at position 28 – Xq28 [150]. This gene 
encodes an enzyme named glucose-6-phosphate dehydrogenase that acts in almost 
all types of cells thus providing normal carbohydrates processing [151]. The most 
important role of G6PD is in RBCs, where this enzyme is involved in protection of 
RBCs from damage and early destruction [152].
Glucose-6-phosphate dehydrogenase deficiency is a genetic disorder that mainly 
affects RBCs, thus causing premature destruction of these cells called hemolysis 
[153]. Besides causing hemolytic anemia, G6PD has an evolutive advantage regard-
ing the protection against malaria. A consequence of the reduced amount of 
functional G6PD makes difficult pathway for parasites to invade RBSc [154]. G6PD 
gene insufficiency is the most frequent in malaria endemic areas. When it comes to 
Mediterranean, the highest noted frequency of this gene is in Mediterranean parts 
of Africa, southern Europe and in the Middle East [153].
Interestingly, G6PD deficient patients in Africa, where this type of deficiency is 
endemic, have milder consequences as well as relatively higher enzyme activity in 
comparison with patients from Mediterranean and Asia [155].
G6PD deficiency gives especially high protection from falciparum malaria infec-
tion [156, 157]. Among more than 400 variants of G6PD that differs in biochemi-
cal characteristics, enzyme kinetics, physicochemical characteristics, and other 
parameters [158] is G6PD B+ which is the most common variant of this enzyme. 
G6PD B+ is used as standard for normal enzyme activity and electrophoretic mobil-
ity and, therefore, for identification of other variants. In the area of Mediterranean, 
special place belongs to G6PD Mediterranean variant [159] which has less than 10% 
of the enzyme activity of G6PD B+ while its electrophoretic mobility is similar to 
G6PD B+ [160]. Two-point mutations in gene for this enzyme were identified. One 
mutation is cytosine to thymine mutation at nucleotide number 563, which causes 
substitution of serine with phenylalanine [161]. At nucleotide number 1311, change 
of cytosine with thymine represents a silent mutation [162].
A research conducted by Barišić et al. in the Dalmatinian region of Croatia 
resulted in discovering a new variant of G6PD named G6PD Split [163]. Change of 
cytosine to guanine at nucleotide 1442 caused substitution of proline with arginine 
which led to moderate enzyme deficiency. Besides this novel variant of G6PD dis-
covered in one patient, other 23 unrelated patients with low G6PD activity had five 
other well-known variants and three patients had uncharacterized forms of G6PD 
mutations. The most represented form found in nine patients was G6PD Cosenza. 
G6PD Cosenza was first found in Calabria region of southern Italy and represents 
the consequence of change of guanine into cytosine at nucleotide 1376. This substi-
tution changes Arginine to Proline [164]. G6PD Cosenza mutation is severe G6PD 
deficiency frequently jointed with hemolysis.
Around 400 million people from all over the World carry at least one deficient 
variant of G6PD gene. The frequency of those mutations varies in different popula-
tions [165]. In Africans and Afro-Americans G6PD A- is the most common mutation 
which has a gene frequency of 11%. G6PD B (Mediterranean) is a more severe defi-
ciency usually found in Mediterranean area. Since Mediterranean represents a large 
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region, the prevalence of this mutation varies from 2 to 20% in Greece, Turkey, and 
Italy, up to the 70% which is the prevalence characteristic for Kurdish Jews [165, 166].
5.4 FY gene polymorphisms and malaria
In addition to the role it plays in transfusion incompatibility and hemolytic 
disease of newborns, Duffy Blood Group System is important in medicine due to its 
association with the invasion of RBCs by the parasite P. vivax. Outside Africa, P. vivax 
is the most widespread malaria parasite species, with 40% of cases in the Eastern 
Mediterranean [167]. Without Duffy antigens on their surface, RBCs are relatively 
resistant to P. vivax [168]. There are six types of Duffy antigens (Fya, Fyb, Fy3, Fy4, 
Fy5, and Fy6), out of which only Fy3 has a clinical significance. Duffy antigens are 
also receptors for chemicals secreted by blood cells during inflammation [169].
Duffy-Antigen Chemokine Receptor (DARC) is a glycosylated transmembrane 
protein receptor which, among other roles, serves as a receptor for P. vivax. DARK 
crosses the membrane seven times and has an extracellular epitope, N-terminal 
domain responsible for RBC invasion by P. vivax merozoites [170, 171]. Two exons 
(FyA and FyB) of FY gene are encoded by the co dominant FyA and FyB alleles 
located on human chromosome 1 [172]. The difference between these two alleles 
is a non-synonymous mutation, specifically substitution of guanine to adenine 
at nucleotide 125, which was enough to determine the two antithetical antigens 
[173]. Based on this variation, four phenotypes within Duffy Blood Group System 
were identified: Fy (a + b-), Fy (a-b+), Fy (a-b-) and Fy (a + b+) [174]. The non-
functional allele Fy*O is the consequence of a mutation in the gene promoter at −33 
nucleotide that changed thymine to cytosine which abolish its expression in the 
erythrocyte cell lineage [175, 176].
Individuals with Fy (a-b-) phenotype are resistant to P. vivax invasion [177]. 
This was shown in the study which included 11 volunteers. The individuals affected 
with malaria were Fy (a+) or Fy (b+). In the countries of West Africa, frequency 
of the Fy (a-b-) phenotype is a high while the incidence of P. vivax malaria is low 
[178]. Virtual absence of P. vivax malaria in populations with widespread DARC 
negativity is the proof of the substantial importance of the Duffy binding protein 
(DBP)–DARC interaction [179]. It is important to emphasize that Fy (a − b−) 
does not protect from P. falciparum which therefore can infect RBCs of any Duffy 
phenotype [169].
While P. falciparum can enter human RBCs through series of receptors on their 
surface, RBCs invasion by P. vivax depends on an interaction with the Fya or Fyb 
antigens [169, 180]. Therefore, in the regions of Africa where Fy (a-b-) phenotype is 
stable within various ethnic groups, the transmission of P. vivax is not usual [181]. On 
the other hand, individuals with Fy (a-b+) or Fy (a + b-) genotypes that express half 
the level of Duffy antigens on RBCs compared to Fy (a-b-) homozygotes are less sen-
sitive to blood stage infection by P. vivax. Therefore, parasitemia by P. vivax might be 
inhibited by total or partial restriction access of P. vivax to Duffy antigen [182, 183].
Phenotypic differences in susceptibility to malaria are the results of Fy gene 
polymorphism. Individuals that carry Duffy antigen-negative allele hidden within 
heterozygous genotype have significantly reduced adherence of the DBP ligand 
domain (DBPII) to erythrocytes [184]. On the other hand, people with Fya phe-
notype have 30–80% lower risk of clinical vivax malaria, but not for falciparum 
malaria [185]. In the countries of Southeast Asia that are the source of P. vivax, the 
Fya allele is fixed [186], while Fyb is represented in the populations in North and 
Northern-central Europe. This kind of distribution of Fy alleles indicates a selective 
advantage against P. vivax malaria [185].
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6. Conclusions
Genetic specificities of Mediterranean region described in this chapter are 
a good example of how important role genetic diversity plays in adaptability to 
local environment. Recognition of these specific genetic traits, of the region, is of 
considerable clinical importance. Carrier identification, genetic counseling and 
prenatal diagnosis still represent a corner stone in the management of thalassemia-
syndromes and various hemoglobiopathies. Due to variable frequencies of different 
MEFV mutations, their genotypes and prevalence should be determined in every 
population, in order to make reference frameworks for mutation screening when 
needed.
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